S&P Futures
3,923.50 +19.75 (+0.51%) Dow Futures
31,594.00 +173.00 (+0.55%) Nasdaq Futures
12,092.75 +52.25 (+0.43%) Russell 2000 Futures
1,782.40 +12.60 (+0.71%) Crude Oil
111.41 +1.84 (+1.68%) Gold
1,824.70 -0.10 (-0.01%)
BioDelivery Sciences International, Inc. (BDSI)
Chart Events
Performance Outlook
| Previous Close | 5.59 |
| Open | 5.60 |
| Bid | 0.00 x 28000 |
| Ask | 0.00 x 36200 |
| Day's Range | 5.59 - 5.60 |
| 52 Week Range | 2.50 - 5.62 |
| Volume | |
| Avg. Volume | 3,352,473 |
| Market Cap | 577.05M |
| Beta (5Y Monthly) | 0.56 |
| PE Ratio (TTM) | 6.82 |
| EPS (TTM) | 0.82 |
| Earnings Date | Aug 02, 2022 - Aug 08, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.38 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for BDSI
Related Research
- BioDelivery Sciences InternatioAnalyst Report: Johnson & JohnsonJohnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. Geographically, just over half of total revenue is generated in the United States.RatingFair ValueEconomic Moat4 days agoMorningstar
- GlobeNewswire
Genenta Announces Nomination of Mark A. Sirgo as Chair
35 years industry experience including as CEO and founder of public company Stephen Squinto steps down as Chair for new role MILAN, Italy and NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, announced the nomination of Mark A. Sirgo, PharmD, an executive leader with over 35 years of pharmaceutical industry experience, as its new Chair
- GlobeNewswire
Collegium Completes the Acquisition of BDSI
STOUGHTON, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) (“Collegium”) today announced that it has completed the acquisition of BioDelivery Sciences International Inc. (Nasdaq: BDSI) (“BDSI”). “This acquisition is a major step forward in our mission to build a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions,” said Joe Ciaffoni, President and Chief Executive Officer of
- Zacks
Merck (MRK) Keytruda Gets Another FDA Nod in Endometrial Cancer
Merck's (MRK) Keytruda gets approval for advanced endometrial carcinoma therapy in certain patients who are not suited for curative surgery or radiation.
